
An Expedient and Efficient Synthesis of an Optically Active Terpene Synthon for $\Delta^{9}\mbox{-}Cannabinoids$

Patrick M. Gordon, Craig Siegel and Raj K. Razdan*

Organix Inc., 65 Cummings Park, Woburn, MA 01801-2105, USA

A three-step synthesis of important, enantiomeric cannabinoid terpene synthons, 1, from (+)- and/or (-)-nopinone is described.


 Δ^9 -Tetrahydrocannabinol (THC) belongs to a class of compounds known as cannabinoids which are responsible for the psychoactive properties of marijuana.^{1,2} The cannabinoids produce, in man and animals, a complex pattern of pharmacological effects some of which are unique to this class of compounds.^{1,2} In spite of extensive pharmacological research, the mechanism(s) by which they exert their effects is not clear.¹ Structure activity relationship (SAR) studies^{1,3} have pointed to a possible receptor mechanism for these drugs but the first direct evidence has come only by the recent




identification of a cannabinoid binding site using radiolabelled 'non-classical' cannabinoid ³H-CP-55940.⁴ Recently, this binding site has been further characterised by cloning experiments.⁵ The structure of CP-55940 is atypical of Δ^9 -THCs, and this has renewed interest in the synthesis of more typical ' Δ^9 -structures' including metabolites and radiolabelled derivatives for both ligand binding and SAR studies. We recently reported the synthesis of an optically active terpene synthon 16 (as a mixture of diastereoisomers) which has proved useful for the synthesis of these type of compounds (*e.g.*, metabolite analogue **2**). We report in this communication a new and shorter route (3 steps) to the synthon 1a,b (obtained as mixtures of diastereoisomers) from optically active (+)and/or (-)-nopinone⁷ (Scheme 1).


Our approach is based on the work of Yoshikoshi and coworkers⁸ who recently reported the cyclobutane ring cleavage of (+)-3-methylnopinone, in high yield using $BF_3 \cdot OEt_2 - Zn(OAc)_2$ in acetic anhydride, with almost no loss of stereochemical integrity. Using the above conditions, (1R)-(+)-nopinone was converted to **3**[†][‡] which was isolated after flash chromatography in good yield (70-85%). Treatment of 3 with allyl ethyl carbonate catalysed by $Pd(OAc)_2$, bis(diphenylphosphino)ethane and Bu₃SnOMe⁹ gave the enone (S)-4, $[\alpha]_{D}^{27}$ -49° (c 0.0615, EtOH), which was determined to be 94% optically pure by comparison with (R)-4 prepared by us previously from compound 6.68 This indicated no loss of optical purity from the starting nopinone.7 In an alternative route, the enol acetate 3 was converted to the keto phenyl selenide 5 using silver trifluoroacetate in benzene followed by treatment with phenylselenenyl bromide.¹⁰ Following the oxidation-elimination sequence^{10,11} (H₂O₂-THF, room temp.) (THF = tetrahydrofuran), compound 5 gave compound 4.

We also attempted the ring opening of the *trans*-3-phenylseleno substituted nopinone (**7b**, Scheme 2). It was prepared along with the *cis* isomer (**7a**, 20%) by treatment of (1*R*)-(+)-nopinone with lithium diisopropylamide followed by phenylselenenyl bromide.¹² The stereochemistry of compounds **7a** and **b** was established by nuclear Overhauser effect studies. When compound **7b** was subjected to Yoshikoshi conditions,⁸ the major product formed, **8** (70%), displayed a very low optical rotation value, $[\alpha]_D^{22} - 0.96^\circ$ (*c* 0.0396, MeOH).¶ Base hydrolysis of the enol acetate functionality in compound **8** (Na₂CO₃ in MeOH–H₂O, 0 °C), followed by the



Scheme 1





oxidation-elimination^{10,11} sequence as described above gave, via compound 5, the enone 4 (40% yield, $[\alpha]_D^{22} 0.62^\circ$ (c 0.0567, MeOH). This optical rotation corresponds to an enantiomeric excess of only 1% and an almost complete loss of optical purity from the starting nopinone. The loss in optical activity was demonstrated to be due to a 1,3 shift of the phenylseleno group $(8a \leftrightarrow 8b)$ by deuterium labelling experiments. Labelled ketone 913 was transformed to ketone 10 as described for 7b. Ketone 10 under Yoshikoshi conditions⁸ gave a mixture of compounds 11 and 12 in a ratio (by ¹H NMR integration of protons H_c and H_d) of 1.17:1, clearly demonstrating the allyl phenylseleno shift presumably via a 1,3 sigmatropic rearrangement. Although this kind of 1,3-shift of allylic selenides¹⁴ and racemisation by allylic rearrangement of similarly constituted allylic esters¹⁵ had been documented, this constitutes an interesting case of racemisation in allylic selenides.

Reaction of an excess of 2-lithio-1,3-dithiane in THF with enone 4^6 and subsequent LAH reduction gave the desired terpene synthon **1b** (82%, 46–59% overall yield from nopinone). Similarly (1*S*)-(-)-nopinone was converted to (*R*)-4 and to the corresponding synthon **1a**. Synthon **1b** was

⁺ All isolated new compounds were characterised by combustion analysis and/or ¹H NMR spectroscopy.

[‡] After the preparation of this manuscript, a communication appeared describing the conversion of (+)-nopinone to enol acetate, **3** in 68% yield [ref. 8(*b*)].

[§] The intermediate epoxy enone **6**⁶ was converted to enone **4** by (i) LiAlH₄ (LAH) reduction in Et₂O; (ii) pyridinium chlorochromate oxidation in CH₂Cl₂ and (iii) Ac₂O-dimethylaminopyridine-pyridine acetylation. Compound (*R*)-**4**, prepared by this route, displayed an $[\alpha]_D^{22}$ value of +58.76° (*c* 0.0573, MeOH).

[¶] It is interesting to note that the *cis*-isomer 7a did not react to any measurable extent under those conditions.

transformed to (+)-11-hydroxy-5-norpentyl-5-(1',1'-dimethylheptyl) THC **2**, as previously described,⁶ without any loss in optical purity from the starting nopinone.

In summary, a short and efficient route to the terpene synthons (R)-1a and (S)-1b is described which should facilitate further studies in the cannabinoid field, which will be reported in due course.

The authors acknowledge financial support from the National Institutes on Drug Abuse (NIDA), Grant No. DA05488.

Received, 21st December 1990; Com. 0/05750I

References

- 1 B. R. Martin, Pharmacol. Rev., 1986, 38, 45.
- 2 W. L. Dewey, Pharmacol. Rev., 1986, 38, 151.
- 3 R. K. Razdan, Pharmacol Rev., 1986, 38, 75.
- 4 W. A. Devane, F. A. Dysarz III, M. R. Johnson, L. S. Melvin and A. C. Howlett, *Mol. Pharmacol.*, 1988, 34, 605; M. Herkenham, A. B. Lynn, M. D. Little, M. R. Johnson, L. S. Melvin, B. R. DeCosta and K. C. Rice, *Proc. Natl. Acad. Sci.*, USA, 1990, 87, 1932.
- 5 L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young and T. I. Bonner, *Nature*, 1990, **346**, 561.

- J. CHEM. SOC., CHEM. COMMUN., 1991
- 6 C. Siegel, P. M. Gordon and R. K. Razdan, J. Org. Chem., 1989, 54, 5428.
- 7 H. C. Brown, S. A. Weissman, P. T. Perumal, and U. P. Dhokte, J. Org. Chem., 1990, 55, 1217 and references cited therein.
- 8 (a) M. Kato, V. P. Kamat, Y. Tooyama and A. Yoshikoshi, J. Org. Chem., 1989, 54, 1536; (b) M. Kato, M. Watanabe, B. Vogler, Y. Tooyama and A. Yoshikoshi, J. Chem. Soc., Chem. Commun., 1990, 1706.
- 9 J. Tsuji, I. Minami and I. Shimizu, *Tetrahedron Lett.*, 1983, 24, 5639.
- 10 H. J. Reich, J. M. Renga and I. L. Reich, J. Am. Chem. Soc., 1975, 97, 5434; D. L. J. Clive, J. Chem. Soc., Chem. Commun., 1973, 695.
- 11 K. Hiroi and S. Sato, Synthesis, 1985, 635.
- 12 For the kinetic controlled alkylation of nopinone to give exclusively *trans*-2-methylnopinone see J. P. Konopelski and C. Djerassi, *J. Org. Chem.*, 1980, **45**, 2297.
- 13 S. G. Levine and B. Gopalarishnan, Tetrahedron Lett., 1979, 699.
- K. B. Sharpless and R. F. Lauer, J. Org. Chem., 1972, 37, 3973;
 H. Nishiyama, K. Itagaki, K. Sakuta and K. Itoh, Tetrahedron Lett., 1981, 22, 5285;
 T. Di Giamberardino, S. Halazy, W. Dumont, and A. Krief, Tetrahedron Lett., 1983, 24, 3413;
 R. G. Shea, J. N. Fitzner, J. E. Fankhauser and P. B. Hopkins, J. Org. Chem., 1984, 49, 3647;
 A. Spaltenstein, P. A. Carpino, F. Miyake and P. B. Hopkins, J. Org. Chem., 1987, 52, 3759.
- 15 H. L. Goering, T. D. Nevitt and E. F. Silversmith, J. Am. Chem. Soc., 1955, 77, 4042.